



Healing today. Curing tomorrow.

SANUWAVE Health, Inc. Announces LHA Life Sciences & Med Tech Day 2010 Presentation

NEW YORK, July 14 /PRNewswire-FirstCall/ -- SANUWAVE Health, Inc. (OTC Bulletin Board: SNWV.OB) announces the following Webcast:

What: LHA Life Sciences & Med Tech Day 2010 Presentation

When: July 20, 2010 @ 12:00 PM Eastern

Where: <http://www.investorcalendar.com/ClientPage.asp?ID=160499>

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at <http://www.investorcalendar.com/ClientPage.asp?ID=160499> or <http://www.investorcalendar.com>.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine company focused on the development and commercialization of non-invasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures.

SANUWAVE's portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. SANUWAVE intends to apply its Pulsed Acoustic Cellular Expression (PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE™, is CE marked for treatment of the skin and subcutaneous soft tissue and recently completed enrollment in an FDA-approved Investigational Device Exemption trial in the U.S. for the treatment of diabetic foot ulcers.

SANUWAVE researches, designs, manufactures, markets and services its products worldwide and believes it has already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved Ossatron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron® and Evotron™ devices in Europe.